. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007 Jun;6(6):501-12. PubMed.


Please login to recommend the paper.


  1. This paper "officially" completes the general failure of cholinesterase inhibitors in MCI. Two possible explanations emerge.

    1. The MCI construct is not clinically valid and needs to be re-evaluated before other trials are started.
    2. MCI is valid as a construct, but inhibitors are fundamentally a bad idea for such cases, because they disrupt compensatory mechanisms that are in force during this period of the dementing process.

    For the interested reader, a meta-analysis of inhibitors in MCI is already published.


    . Cholinesterase inhibitors in mild cognitive impairment: a meta-analysis of randomized controlled trials. Neurol Neurochir Pol. 2007 Jan-Feb;41(1):13-21. PubMed.

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. FDA Gives a Nod for Alzheimer's and Parkinson's Biomarkers